125 related articles for article (PubMed ID: 20084781)
1. Metastatic bone disease: evaluation by functional imaging in correlation with morphologic modalities.
Elgazzar AH; Kazem N
Gulf J Oncolog; 2009 Jan; (5):9-21. PubMed ID: 20084781
[TBL] [Abstract][Full Text] [Related]
2. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone.
Ghanem N; Uhl M; Brink I; Schäfer O; Kelly T; Moser E; Langer M
Eur J Radiol; 2005 Jul; 55(1):41-55. PubMed ID: 15950100
[TBL] [Abstract][Full Text] [Related]
4. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
Liu FY; Yen TC; Chen MY; Lai CH; Chang TC; Chou HH; Hong JH; Chen YR; Ng KK
Cancer; 2009 Dec; 115(23):5470-80. PubMed ID: 19739235
[TBL] [Abstract][Full Text] [Related]
5. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities.
Even-Sapir E
J Nucl Med; 2005 Aug; 46(8):1356-67. PubMed ID: 16085595
[TBL] [Abstract][Full Text] [Related]
6. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Flusser G; Zuriel L; Kollender Y; Lerman H; Lievshitz G; Ron I; Mishani E
J Nucl Med; 2004 Feb; 45(2):272-8. PubMed ID: 14960647
[TBL] [Abstract][Full Text] [Related]
7. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease.
Horger M; Bares R
Semin Nucl Med; 2006 Oct; 36(4):286-94. PubMed ID: 16950146
[TBL] [Abstract][Full Text] [Related]
8. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
9. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.
Seemann MD; Meisetschlaeger G; Gaa J; Rummeny EJ
Eur J Med Res; 2006 Feb; 11(2):58-65. PubMed ID: 16504962
[TBL] [Abstract][Full Text] [Related]
11. PET/CT in malignant bone disease.
Even-Sapir E
Semin Musculoskelet Radiol; 2007 Dec; 11(4):312-21. PubMed ID: 18324596
[TBL] [Abstract][Full Text] [Related]
12. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
Basu D; Siegel BA; McDonald DJ; Nussenbaum B
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
14. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
15. Bone imaging in metastatic breast cancer.
Hamaoka T; Madewell JE; Podoloff DA; Hortobagyi GN; Ueno NT
J Clin Oncol; 2004 Jul; 22(14):2942-53. PubMed ID: 15254062
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
17. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
18. Skeletal metastases: an update of the literature with pictorial review.
Zampakis P; Romanos O; Kraniotis P; Solomou EK
J BUON; 2011; 16(1):24-37. PubMed ID: 21674846
[TBL] [Abstract][Full Text] [Related]
19. [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy].
Ketelsen D; Röthke M; Aschoff P; Merseburger AS; Lichy MP; Reimold M; Claussen CD; Schlemmer HP
Rofo; 2008 Aug; 180(8):746-52. PubMed ID: 18512192
[TBL] [Abstract][Full Text] [Related]
20. Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy.
Goudarzi B; Kishimoto R; Komatsu S; Ishikawa H; Yoshikawa K; Kandatsu S; Obata T
Magn Reson Imaging; 2010 Apr; 28(3):372-9. PubMed ID: 20106624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
